 Life Science Investor Mandates
(Jan. 25 - Jan. 31
)
|
|
|
|
|
Invests Up to $30M in Derisked Life Science Investment Opportunities
|
|
Seeks Various Technologies with Focus in Antivirals, Oncology, CNS, and Diabetes
|
|
Searching Globally for Early-Stage Precision Medicine Diagnostics and Mobile Health
|
|
Invests in Smart Devices and Digital Health Technologies
|
|
Click to see investors that are a fit for your product and stage of development
|
|
Click here if you are a service provider and want to see a list of funded life science companies that are a fit for you
|
|
Click here if you want to receive free, targeted early stage dealflow for your life science investment firm
|
|
|
With RESI returning to MaRS in Toronto on April 10th, LSN has prepared a full day agenda of panel and workshop content. In addition to RESI's high quality one-on-one partnering, attendees will also have the opportunity to hear directly from investors on a variety of topics in early stage fundraising.
For this RESI event in Toronto, we are introducing panels on
Tech Transfer and on
Government Research Funding, both of which are key topics in the local ecosystem. RESI on MaRS will also see the return of perennial RESI sessions such as
Early Stage Therapeutics, Medical Device Investors, Diagnostics and
Digital Health. Additionally, RESI will include panels on increasingly popular topic areas -
Family Offices, Genomics, and
Big Data & Algorithms in Healthcare. Finally, RESI's Track 4 presents 4 workshops and panels focused on
Asia-North America Partnerships, with deep dives on
Cross-Border In-Licensing, the
Asia Investors Landscape, and more...
|
 |
In last week's newsletter, you may have read about LSN's review of 2017 licensing deals and how
licensing deals are happening even earlier. Despite the high risk, pharmaceutical companies all across the globe are aggressively seeking partnership opportunities in hopes of identifying breakthrough therapies.
During RESI San Francisco - our first conference of the year - we invited 5 panelists from the world's leading pharmaceutical companies to share their insights on early-stage partnerships. How do they assess value? How can companies differentiate themselves, especially those who are in an overcrowded space?
Moderated by
Chris Haskell,
VP, Head of West Coast Innovation Center, Bayer HealthCare, the Big Pharma panelists were:
- Kevin Lynch, Vice President, Search & Evaluation, AbbVie
- Chris Sheldon, Head, Oncology Search & Evaluation, AstraZeneca
- Lesley Stolz, Head, JLABS California, Johnson & Johnson Innovation
- Chris DeRespino, Director, Transactions, Amgen
|
|
Life Science Nation (LSN) has created a fully integrated global matching platform that allows for buyers and sellers in the early stage life science arena to find and connect with each other based on a company's stage of development and product. An integral part of LSN's matching platform is the Redefining Early Stage Investments (RESI) conference series that that currently is held six times a year in life science technology hubs throughout North America and Europe. RESI is a one-of-a-kind partnering event, in that the event has a 1:1 ratio of scientist/entrepreneurs to investors/strategic partners. Hundreds of investors and strategics regularly attend the RESI conference to source technology deals.
LSN has been approached over the last two years regarding bringing the RESI conference to China. The LSN Research team has done significant outreach to help establish a strong ecosystem of China-based investors who speak on our RESI panels and use RESI as a vehicle to source and vet diverse technology assets across the silos of drugs, devices and diagnostics and digital health...
|
|
|
Created & Produced by
|
 |
|
|
|
